Latest Genmab News & Updates

See the latest news and media coverage for Genmab. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Genmab

Therapeutic antibody developer

genmab.com
Headquarters
2500 Valby, Denmark
Company type
Public company
Number of employees
2,500–5,000

Latest news about Genmab

Company announcements

  • Genmab

    Genmab reports DARZALEX Q1 2026 net sales

    Worldwide net trade sales totaled USD 3,964 million, including USD 2,208 million in the U.S. and USD 1,756 million elsewhere; Genmab receives royalties from J&J.

  • Genmab

    Genmab names Margarida Duarte General Manager Europe and Emerging Markets

    She brings over 20 years of biotech leadership in oncology. She will oversee commercial operations across these markets from Zug, Switzerland.

  • Genmab

    Genmab corrects share price in announcement No. 13

    The price was erroneously reported as DKK 0.00; correct price is DKK 1,867.50 for transactions by managerial employees and associated persons.

  • Genmab

    Genmab discloses transactions in shares by managerial employees

    Transactions comply with Market Abuse Regulation. Includes vesting and net settlement of restricted stock units for Jan van de Winkel and Anthony Pagano.

Unlock all announcements with a

Media coverage

  • Euroinvestor

    Danish giant rises after Goldman Sachs recommendation

    The Danish biotech company Genmab rises 2.4 pct. and thus takes the lead in the C25 index. The rise comes after Goldman Sachs has changed its view on...

  • Barron's

    Genmab A/S ADR

    Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least...

  • Pharmaphorum

    Multiple myeloma drug Blenrep backed for wider NHS use

    The revitalisation of GSK's Blenrep has continued with the news that the NHS in England can use the BCMA-targeting multiple myeloma drug more widely. In...

  • MSN

    Genmab A (GMAB) price target decreased by 61.97% to 34.46

    The average one-year price target for Genmab A (NasdaqGS:GMAB) has been revised to $34.46 / share. This is a decrease of ...

Unlock all articles with a

Never miss news about Genmab

Track Genmab and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Genmab competitors & trending companies

Browse news for competitors to Genmab and other trending companies.